治疗选择-话题@MedSci - williamhill asia

#治疗选择#

87篇内容 | 1824人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1772763, encodeId=10451e72763ab, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, objectTitle=解读急淋患者的维持治疗选择和必要性, objectType=article, longId=739275, objectId=35c6e392757c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35c6e392757c, replyNumber=0, likeNumber=61, createdTime=2022-10-20, rootId=0, userName=liye789132264, userId=015a38388258, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35c6e392757c, moduleTitle=解读急淋患者的维持治疗选择和必要性, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=35c6e392757c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1772761, encodeId=7e381e7276178, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, objectTitle=多国威廉亚洲博彩公司建议综合推荐——尽管新的降糖疗法不断出现，磺脲类仍是理想的降糖药物治疗选择, objectType=article, longId=735847, objectId=d5c5e3584748, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5c5e3584748, replyNumber=0, likeNumber=71, createdTime=2023-04-11, rootId=0, userName=liye789132264, userId=015a38388258, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5c5e3584748, moduleTitle=多国威廉亚洲博彩公司建议综合推荐——尽管新的降糖疗法不断出现，磺脲类仍是理想的降糖药物治疗选择, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=d5c5e3584748)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1772762, encodeId=44881e72762f7, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, objectTitle=新诊断T2DM患者的降糖治疗选择, objectType=article, longId=737611, objectId=51eee376119d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51eee376119d, replyNumber=0, likeNumber=67, createdTime=2023-05-23, rootId=0, userName=liye789132264, userId=015a38388258, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51eee376119d, moduleTitle=新诊断T2DM患者的降糖治疗选择, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=51eee376119d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1772760, encodeId=87971e7276093, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, objectTitle=高危MCL治疗选择-患者的管理路径, objectType=article, longId=735454, objectId=1104e35454fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1104e35454fb, replyNumber=0, likeNumber=107, createdTime=2023-01-22, rootId=0, userName=liye789132264, userId=015a38388258, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1104e35454fb, moduleTitle=高危MCL治疗选择-患者的管理路径, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1104e35454fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1772759, encodeId=849b1e727593f, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, objectTitle=J Ethnopharmacol：年龄相关性黄斑变性不可忽视的中医治疗选择, objectType=article, longId=729752, objectId=a232e2975204, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a232e2975204, replyNumber=0, likeNumber=56, createdTime=2022-10-23, rootId=0, userName=liye789132264, userId=015a38388258, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a232e2975204, moduleTitle=J Ethnopharmacol：年龄相关性黄斑变性不可忽视的中医治疗选择, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=a232e2975204)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1772758, encodeId=c7051e72758d3, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, objectTitle=乳房再造手术决策中的认知偏差和治疗选择, objectType=article, longId=724483, objectId=f6bae2448315, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6bae2448315, replyNumber=0, likeNumber=82, createdTime=2022-11-18, rootId=0, userName=liye789132264, userId=015a38388258, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6bae2448315, moduleTitle=乳房再造手术决策中的认知偏差和治疗选择, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f6bae2448315)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1772753, encodeId=d01e1e72753bc, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, objectTitle=JACC：肺动脉高压患者，初始治疗选择三联还是二联药物治疗？, objectType=article, longId=218277, objectId=55ae2182e7a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55ae2182e7a8, replyNumber=0, likeNumber=90, createdTime=2022-05-02, rootId=0, userName=liye789132264, userId=015a38388258, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55ae2182e7a8, moduleTitle=JACC：肺动脉高压患者，初始治疗选择三联还是二联药物治疗？, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=55ae2182e7a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1772752, encodeId=be621e72752b5, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, objectTitle=一文了解角化棘皮瘤的治疗选择, objectType=article, longId=217131, objectId=b7ae21e13197, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7ae21e13197, replyNumber=0, likeNumber=93, createdTime=2022-06-16, rootId=0, userName=liye789132264, userId=015a38388258, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7ae21e13197, moduleTitle=一文了解角化棘皮瘤的治疗选择, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=b7ae21e13197)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1772757, encodeId=d7c91e72757da, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, objectTitle=2022 AACR：ORR超60%，本土创新药谷美替尼有望为METex14跳跃突变NSCLC患者带来全新治疗选择！, objectType=article, longId=724037, objectId=8223e24037e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8223e24037e2, replyNumber=0, likeNumber=98, createdTime=2022-05-29, rootId=0, userName=liye789132264, userId=015a38388258, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8223e24037e2, moduleTitle=2022 AACR：ORR超60%，本土创新药谷美替尼有望为METex14跳跃突变NSCLC患者带来全新治疗选择！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=8223e24037e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1772750, encodeId=24a31e72750d6, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, objectTitle=Lancet Gastroent Hepatol：BI 695501，克罗恩病的潜在新治疗选择！, objectType=article, longId=215896, objectId=e500215896a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e500215896a1, replyNumber=0, likeNumber=72, createdTime=2022-03-15, rootId=0, userName=liye789132264, userId=015a38388258, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e500215896a1, moduleTitle=Lancet Gastroent Hepatol：BI 695501，克罗恩病的潜在新治疗选择！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=e500215896a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1772746, encodeId=c3351e727461b, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, objectTitle=Ann Hematol：ixazomib口服治疗方案有望成为NDMM患者的良好替代治疗选择, objectType=article, longId=212449, objectId=882221244968, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=882221244968, replyNumber=0, likeNumber=61, createdTime=2022-03-21, rootId=0, userName=liye789132264, userId=015a38388258, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=882221244968, moduleTitle=Ann Hematol：ixazomib口服治疗方案有望成为NDMM患者的良好替代治疗选择, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=882221244968)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1772754, encodeId=35011e72754df, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, objectTitle=J Clin Oncol：nab-西罗莫司有望成为恶性PEComa的治疗选择！, objectType=article, longId=218576, objectId=495e2185e650, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=495e2185e650, replyNumber=0, likeNumber=69, createdTime=2021-11-04, rootId=0, userName=liye789132264, userId=015a38388258, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=495e2185e650, moduleTitle=J Clin Oncol：nab-西罗莫司有望成为恶性PEComa的治疗选择！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=495e2185e650)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1772756, encodeId=427a1e7275669, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, objectTitle=Nat Commun：p32 CAR-T细胞：胶质母细胞瘤的潜在治疗选择, objectType=article, longId=292171, objectId=e81a2921e11f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e81a2921e11f, replyNumber=0, likeNumber=57, createdTime=2022-10-26, rootId=0, userName=liye789132264, userId=015a38388258, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e81a2921e11f, moduleTitle=Nat Commun：p32 CAR-T细胞：胶质母细胞瘤的潜在治疗选择, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=e81a2921e11f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1772745, encodeId=a81d1e727457b, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, objectTitle=NEJM：3岁以下儿童复发性急性中耳炎的治疗选择——鼓室造口管植入vs抗菌治疗, objectType=article, longId=211278, objectId=be932112e871, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be932112e871, replyNumber=0, likeNumber=122, createdTime=2021-12-21, rootId=0, userName=liye789132264, userId=015a38388258, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be932112e871, moduleTitle=NEJM：3岁以下儿童复发性急性中耳炎的治疗选择——鼓室造口管植入vs抗菌治疗, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=be932112e871)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1772755, encodeId=d7f71e727557e, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, objectTitle=Liver Cancer：Atezolizumab (ATEZO) + bevacizumab (BEVA)一线治疗晚期HCC进展后，二线治疗选择对比, objectType=article, longId=221201, objectId=587522120103, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=587522120103, replyNumber=0, likeNumber=62, createdTime=2022-09-27, rootId=0, userName=liye789132264, userId=015a38388258, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=587522120103, moduleTitle=Liver Cancer：Atezolizumab (ATEZO) + bevacizumab (BEVA)一线治疗晚期HCC进展后，二线治疗选择对比, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=587522120103)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1772751, encodeId=8e761e72751f9, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, objectTitle=一文读懂角化棘皮瘤的治疗选择, objectType=article, longId=217112, objectId=4fd221e11268, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4fd221e11268, replyNumber=0, likeNumber=105, createdTime=2022-04-09, rootId=0, userName=liye789132264, userId=015a38388258, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4fd221e11268, moduleTitle=一文读懂角化棘皮瘤的治疗选择, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=4fd221e11268)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1772747, encodeId=91161e727470d, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, objectTitle=Nat Commun：p32 CAR-T细胞：胶质母细胞瘤的潜在治疗选择, objectType=article, longId=212792, objectId=f30c212e92da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f30c212e92da, replyNumber=0, likeNumber=70, createdTime=2022-04-01, rootId=0, userName=liye789132264, userId=015a38388258, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f30c212e92da, moduleTitle=Nat Commun：p32 CAR-T细胞：胶质母细胞瘤的潜在治疗选择, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f30c212e92da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1772749, encodeId=d64a1e7274929, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, objectTitle=NEJM：HIV感染二线治疗选择——度鲁特韦方案vs达芦那韦方案, objectType=article, longId=214784, objectId=2ebb214e8446, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ebb214e8446, replyNumber=0, likeNumber=75, createdTime=2021-08-25, rootId=0, userName=liye789132264, userId=015a38388258, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ebb214e8446, moduleTitle=NEJM：HIV感染二线治疗选择——度鲁特韦方案vs达芦那韦方案, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=2ebb214e8446)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1772744, encodeId=48e91e72744e9, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, objectTitle=Nat Commun：用临床转录组方法对急性髓性白血病患者进行分层和治疗选择 , objectType=article, longId=210795, objectId=0a46210e95fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a46210e95fb, replyNumber=0, likeNumber=68, createdTime=2021-07-29, rootId=0, userName=liye789132264, userId=015a38388258, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a46210e95fb, moduleTitle=Nat Commun：用临床转录组方法对急性髓性白血病患者进行分层和治疗选择 , moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0a46210e95fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1772742, encodeId=700a1e727423c, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, objectTitle=TAG: 年龄影响炎症性肠病患者的疾病特征和治疗选择吗？, objectType=article, longId=208788, objectId=c430208e8879, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c430208e8879, replyNumber=0, likeNumber=108, createdTime=2021-10-31, rootId=0, userName=liye789132264, userId=015a38388258, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c430208e8879, moduleTitle=TAG: 年龄影响炎症性肠病患者的疾病特征和治疗选择吗？, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=c430208e8879)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

治疗选择

2020-05-29

liye789132264 (审核中...)

前往app查看评论内容

#治疗选择#

解读急淋患者的维持治疗选择和必要性

2022-10-20

liye789132264 (审核中...)

前往app查看评论内容

#治疗选择#

多国威廉亚洲博彩公司建议综合推荐——尽管新的降糖疗法不断出现，磺脲类仍是理想的降糖药物治疗选择

2023-04-11

liye789132264 (审核中...)

前往app查看评论内容

#治疗选择#

新诊断T2DM患者的降糖治疗选择

2023-05-23

liye789132264 (审核中...)

前往app查看评论内容

#治疗选择#

高危MCL治疗选择-患者的管理路径

2023-01-22

liye789132264 (审核中...)

前往app查看评论内容

#治疗选择#

J Ethnopharmacol：年龄相关性黄斑变性不可忽视的中医治疗选择

2022-10-23

liye789132264 (审核中...)

前往app查看评论内容

#治疗选择#

乳房再造手术决策中的认知偏差和治疗选择

2022-11-18

liye789132264 (审核中...)

前往app查看评论内容

#治疗选择#

JACC：肺动脉高压患者，初始治疗选择三联还是二联药物治疗？

2022-05-02

liye789132264 (审核中...)

前往app查看评论内容

#治疗选择#

一文了解角化棘皮瘤的治疗选择

2022-06-16

liye789132264 (审核中...)

前往app查看评论内容

#治疗选择#

2022 AACR：ORR超60%，本土创新药谷美替尼有望为METex14跳跃突变NSCLC患者带来全新治疗选择！

2022-05-29

liye789132264 (审核中...)

前往app查看评论内容

#治疗选择#

Lancet Gastroent Hepatol：BI 695501，克罗恩病的潜在新治疗选择！

2022-03-15

liye789132264 (审核中...)

前往app查看评论内容

#治疗选择#

Ann Hematol：ixazomib口服治疗方案有望成为NDMM患者的良好替代治疗选择

2022-03-21

liye789132264 (审核中...)

前往app查看评论内容

#治疗选择#

J Clin Oncol：nab-西罗莫司有望成为恶性PEComa的治疗选择！

2021-11-04

liye789132264 (审核中...)

前往app查看评论内容

#治疗选择#

Nat Commun：p32 CAR-T细胞：胶质母细胞瘤的潜在治疗选择

2022-10-26

liye789132264 (审核中...)

前往app查看评论内容

#治疗选择#

NEJM：3岁以下儿童复发性急性中耳炎的治疗选择——鼓室造口管植入vs抗菌治疗

2021-12-21

liye789132264 (审核中...)

前往app查看评论内容

#治疗选择#

Liver Cancer：Atezolizumab (ATEZO) + bevacizumab (BEVA)一线治疗晚期HCC进展后，二线治疗选择对比

2022-09-27

liye789132264 (审核中...)

前往app查看评论内容

#治疗选择#

一文读懂角化棘皮瘤的治疗选择

2022-04-09

liye789132264 (审核中...)

前往app查看评论内容

#治疗选择#

Nat Commun：p32 CAR-T细胞：胶质母细胞瘤的潜在治疗选择

2022-04-01

liye789132264 (审核中...)

前往app查看评论内容

#治疗选择#

NEJM：HIV感染二线治疗选择——度鲁特韦方案vs达芦那韦方案

2021-08-25

liye789132264 (审核中...)

前往app查看评论内容

#治疗选择#

Nat Commun：用临床转录组方法对急性髓性白血病患者进行分层和治疗选择

2021-07-29

liye789132264 (审核中...)

前往app查看评论内容

#治疗选择#

TAG: 年龄影响炎症性肠病患者的疾病特征和治疗选择吗？

2021-10-31

科室
- - 订阅+
  - 更多科室
工具
服务